Imatron Announces Ten EBT Scanner Shipments in Second Quarter; First Imatron C-300 EBT Scanner Installed At the Cooper Clinic in Dallas.

Business Editors & Health/Medical Writers

BIOWIRE2K

SO. SAN FRANCISCO, Calif.--(BW HealthWire)--July 9, 2001

Record Shipments Include International Sale to

Xijing Hospital in China

Imatron Inc. (Nasdaq:IMAT) announced today that it sold ten electron beam tomography (EBT) scanners during its second quarter ended June 30, 2001. The Company's record EBT scanner shipments include an international sale to Xijing PLA Hospital in Xian, China. The Company plans to release its second quarter financial results in early August.

Xijing PLA Hospital is a 1,000-bed, multidisciplinary teaching hospital with 12 teaching and research sections and 44 specialized departments. The hospital maintains 200 senior technical personnel members and more than 1,000 staff members. The hospital has won worldwide recognition in the fields of PTCA (percutaneous transluminal coronary (balloon) angioplasty), RFCA (radio frequency catheter ablation), cardiac valvoplasty, and surgical treatment for complex congenital heart diseases. Xijing Hospital treats more than 600,000 outpatients and 110,000 emergency cases annually.

S. Lewis Meyer, CEO of Imatron, commented, "We are pleased to announce sales of ten EBT scanners during the second quarter. Our EBT scanner sale to Xijing Hospital signifies what we believe will be a notable increase in international sales in the coming quarters. We also continued to ship scanners to many multi-system purchasers, who continue to aggressively develop and expand their imaging center networks nationwide utilizing our proprietary EBT technology. During the quarter we also introduced a new scanner model, the C-300, which, as a result of the upgrade costs associated with this scanner model changeover, will have a modest impact on net income for the quarter. Our new C-300 EBT scanner provides important and exciting new hardware and software capabilities to our customers. Unique cardiac functional imaging, multi-phase electron beam angiography (EBA), and PC-based image reconstruction give Imatron both important competitive advantages in cardiovascular imaging and validation of our continuing investment in EBT technology development. The first C-300 scanner was shipped to the Cooper Clinic in Dallas, which represents the third Imatron EBT system purchased by Cooper Clinic. Cooper Clinic, founded in 1970 by Kenneth H. Cooper, M.D., is located at the 30-acre campus of the Cooper Aerobics Center of Dallas, and is known throughout the world for its expertise in preventive medicine. The clinic offers a wide range of preventive, diagnostic and rehabilitative services. The clinic's 16 staff physicians specialize in cardiology, internal medicine, preventive medicine, radiology, nuclear medicine, cardiac rehabilitation, cholesterol management and stress medicine. We have been extremely pleased with the positive response to our introduction of the C-300. The significant new capabilities of the C-300 EBT scanner model should accelerate EBT scanner sales during the remainder of 2001. We remain on track to meet our goal of selling more than 40 EBT scanners in 2001."

Meyer continued, "It is also important to note that on May 15, 2001, the National Cholesterol Education Program (NCEP) issued new clinical practice guidelines for the prevention and management of high cholesterol in adults. The new guidelines are expected to significantly increase the number of Americans currently being treated for high cholesterol, including increasing to 36 million from 13 million, the number of people using cholesterol-lowering drugs. We believe these new guidelines represent a serious economic challenge to the American healthcare system and are certain that EBT can play a very important role in focusing these effective and expensive treatments on those who most need it and can most likely benefit from this investment."

According to Harvey Hecht, MD, FACC, "Guidelines for subclinical coronary disease definition by plaque imaging will ultimately become part of national health policy. We hope that the NCEP panel will react soon to the increasing amount of data and give imaging methods a more prominent place in risk assessment strategies. Currently available imaging, especially EBT, allows us to determine if you already have disease rather than simply the risk of developing disease."

For additional information about Imatron, visit the company's web site at www.imatron.com.

Imatron Inc. is primarily engaged in designing, manufacturing, marketing, and servicing high performance electron beam tomography (EBT) scanners based on the Company's proprietary EBT technology. Imatron's EBT scanner is now in use at more than 150 major medical facilities and imaging centers around the world, including Abbott-Northwestern Hospital, Arizona Heart Institute, Cedars-Sinai Medical Center in Los Angeles, CA, Edward Cardiovascular Institute, Hackensack University Medical Center, Harbor-UCLA Medical Center, Mayo Clinic, Mount Sinai Medical Center in Miami Beach, FL, St. Francis Hospital, Stanford University, UCLA Medical Center, University of Illinois, University of Iowa, University of Pittsburgh Medical Center, Alfried Krupp Krankenhaus, Essen, Landeskrankenhaus in Graz, Austria, Cardiology Research Centre in Moscow, Russia, FAU Erlangen-Nurnberg in Erlangen, Germany, Beijing Hospital in China, BodyScan Imaging Center of Kansas City, BodyScan Imaging Center of Scottsdale, Cardiac Plus, Cooper Clinic, Heart Savers of Irvine, Holistica Hawaii, ITG/HeartScan Imaging, LifeScore of San Diego, Michigan Heart Imaging, Ohio Heart, University HeartScan of Manhattan, and Vital Imaging (La Jolla, Dallas, Houston and Orange County).

Except for the historical information contained herein, the matters discussed in this news release may contain forward-looking statements that are based on current expectations and estimates about the industry in which Imatron operates, the estimated impact of certain technological advances, the estimated impact of published research studies on scanner sales and procedures, as well as management's beliefs and assumptions. It is important to note that the Company's actual results could differ materially from those projected in such forward-looking statements. The factors that could cause actual results to differ materially include, among others; failed clinical demonstration of certain asserted technological advantages and diagnostic capabilities; reliance on product distributors; competition in the diagnostic imaging market; failure to improve product reliability or introduce new product models and enhancements; delays in production and difficulty in obtaining components and sub-assemblies from limited sources of supply; inability to meet cash-on-delivery or prepayment terms from vendors; determinations by regulatory and administrative government authorities; patent expiration and denial of patent applications; the high cost of the scanner as compared to commercially available CT scanners; and the risk factors listed from time to time in the Company's Securities and Exchange Commission reports, including their reports on Form 10-K for their current fiscal year.